Impact BioMedical Inc. (NYSE American: IBO)’s Post

When it comes to choosing an eClinical partner, biotechs and emerging biopharma shouldn’t have to choose between working with an established, full-service company and a smaller, provider with a more hands-on approach. With Signant Biotech, you get the best of both worlds. Learn how: https://hubs.li/Q02QNP5j0

Spartan Capital Securities, LLC is excited to welcome Impact BioMedical Inc. (NYSE American: IBO) as a presenting company at the Spartan Capital Investor Conference 2024, taking place on November 4th at The Pierre Hotel in New York City.   Impact Biomedical Inc.(IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships. By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals, over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncologic, and inflammatory diseases. In addition to our existing efforts, we continually search for, and evaluate, other potential new offerings to add to our portfolio. Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBIO technologies in exchange for milestone, and royalty payments. Impact BioMedical Inc. (NYSE American: IBO)'s leadership team includes Frank D. Heuszel, Mark Suseck, Todd Macko, CPA, and many other talented individuals. The Spartan Capital Investor Conference brings together an impressive array of public company executives, institutional investors, and thought leaders in the U.S. capital markets. With over 30 companies slated to present, the event promises unparalleled networking opportunities.   To secure your place at this premier event, visit: https://lnkd.in/enQCABXZ   #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024

Spartan Capital Securities, LLC is excited to welcome Impact BioMedical Inc. (NYSE American: IBO) as a presenting company at the Spartan Capital Investor Conference 2024, taking place on November 4th at The Pierre Hotel in New York City.   Impact Biomedical Inc.(IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships. By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals, over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncologic, and inflammatory diseases. In addition to our existing efforts, we continually search for, and evaluate, other potential new offerings to add to our portfolio. Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBIO technologies in exchange for milestone, and royalty payments. Impact BioMedical Inc. (NYSE American: IBO)'s leadership team includes Frank D. Heuszel, Mark Suseck, Todd Macko, CPA, and many other talented individuals. The Spartan Capital Investor Conference brings together an impressive array of public company executives, institutional investors, and thought leaders in the U.S. capital markets. With over 30 companies slated to present, the event promises unparalleled networking opportunities.   To secure your place at this premier event, visit: https://lnkd.in/enQCABXZ   #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024

The August 2024 edition of our Pharma Services: Drug Development BlueBook is now available. Read why C-suite executives and private equity professionals in the health sciences industries turn to our publication for valuation trends, M&A activity, and transaction reporting. Here's a glimpse into the August 2024 edition: 📌Anju was acquired by Valsoft 📌Vion Biosciences announced its acquisition of Ansh Labs 📌Ambrosa Biosciences closed a $16MM Series A Financing, led by Boulder Ventures and BVF Partners Download the full August edition now: https://hubs.li/Q02Vn-HG0 #Insights #MergersAndAcquisitions #PrivateEquity #FinancialNews

ClavystBio CEO Khoo Shih sat down with Citeline Commercial Scrip’s Mandy Jackson to discuss the growing traction in the biotech market. Financing is showing signs of improvement, driven by increased M&A activity from big pharma acquiring smaller firms at attractive valuations. IPOs for clinical-stage companies are also on the rise. Khoo Shih highlighted that while financing prospects are improving, success hinges on companies with a well-articulated story and clear milestones: Key takeaways: • Clarity in Milestones: This is a pivotal time for biotechs to sharpen strategies and communicate their milestones. Investors are looking for companies that can articulate a clear path to value-creating clinical milestones. • Platform Potential: While platforms are valued, the real focus is on the progression of drug candidates. • Strong Insider Commitment: Demonstrating robust internal support is crucial. Read the full article here (for subscribers only): https://lnkd.in/g7DZjZwz

PharmAust Completes Successful Share Purchase Plan We are thrilled to announce the completion of our Share Purchase Plan (SPP), which raised an impressive $7.8 million, significantly exceeding our initial $2 million target. This strong demand reflects the exceptional support from our shareholders, who were offered the same terms as our recently completed $10 million institutional Placement. The combined $17.8 million from the SPP and Placement substantially strengthens our balance sheet and minimizes future funding needs as we advance the development of monepantel for ALS and other neurodegenerative conditions. Our Chairman, Sergio Duchini, extends his heartfelt gratitude to all shareholders for their unwavering support and confidence in PharmAust’s strategic direction. PharmAust Chairman Sergio Duchini commented: 'With these funds, we are well-positioned to commence the HEALEY ALS Platform Trial and achieve significant milestones in H2 CY2024. We look forward to keeping you updated on our progress." Thank you to all our shareholders for your continued support! #PharmAust #ASX #ALSResearch #NeurodegenerativeDiseases #Biotech #CapitalRaising #SharePurchasePlan

While I'm just an outsider looking in, Grifols' recent decision to reject Brookfield's €6.5B (~$6.8B) offer seems to underscore a powerful truth in our industry: value goes beyond financial figures. For companies like Grifols, known for pioneering plasma-based therapies, the choice of a partner isn't merely transactional—it's strategic. It's a vivid example of how life sciences businesses prioritize long-term potential, innovation, and alignment over immediate monetary gain. Alignment is everything in pharma-private equity relationships, and partnerships in our sector must support the broader mission of improving patient outcomes, driving sustainable growth, and enhancing healthcare ecosystems. As the industry evolves to focus on specialized treatments and innovation, we must continue to advocate for collaborations that honor the science, the patients, and the potential—not just the price tag. https://lnkd.in/dGM469J6

Implementing a carefully considered first launch strategy can have long-lasting effects on a biopharma organization’s success. In this webinar, we look at the data to discover trends in tech, commercialization, partnering and more. Join us on Jan. 8 for this Impact Webinar: https://bit.ly/4gcxmGH #JPM2025 #ZSAtJPM #HealthcareInnovation

Implementing a carefully considered first launch strategy can have long-lasting effects on a biopharma organization’s success. In this webinar, we look at the data to discover trends in tech, commercialization, partnering and more. Join us on Jan. 8 for this Impact Webinar: https://bit.ly/4gcxmGH #JPM2025 #ZSAtJPM #HealthcareInnovation

Implementing a carefully considered first launch strategy can have long-lasting effects on a biopharma organization’s success. In this webinar, we look at the data to discover trends in tech, commercialization, partnering and more. Join us on Jan. 8 for this Impact Webinar: https://bit.ly/4gcxmGH #JPM2025 #ZSAtJPM #HealthcareInnovation